Intellia Therapeutics Inc. (NTLA)
NTLA Q2 Earnings In Line, Top Line Misses on Lower Regeneron Revenues
Intellia's Q2 loss matches estimates, but revenues fall 46.2% as lower Regeneron collaboration revenues weigh on results.
Intellia Therapeutics Q2 Earnings Call Highlights
Intellia Therapeutics NASDAQ: NTLA said it advanced its lead gene-editing programs during the second quarter, highlighting positive Phase III results for lonvo-z in hereditary angioedema and the resumption of enrollment in Phase III studies of nex-z for transthyretin amyloidosis.
Intellia Therapeutics, Inc. (NTLA) Reports Q2 Loss, Lags Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.8 per share in line with the Zacks Consensus Estimate. This compares to a loss of $0.99 per share a year ago.
NTLA Surges 38% in a Month: Should You Buy, Sell or Hold the Stock?
Intellia gains 38% in a month as additional positive phase III lonvo-z data and other pipeline progress boost investor optimism.
NTLA Posts Strong Additional Phase III Data From HAE Study, Stock Up
Intellia jumps after additional phase III HAELO data showed lonvo-z cut on-demand-treated attacks by 89% and moderate-to-severe episodes by 91%.
Strength Seen in Intellia Therapeutics (NTLA): Can Its 23.2% Jump Turn into More Strength?
Intellia Therapeutics (NTLA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Intellia Therapeutics (NTLA) Down 7.9% Since Last Earnings Report: Can It Rebound?
Intellia Therapeutics (NTLA) reported earnings 30 days ago. What's next for the stock?
Intellia Therapeutics - Steady Progress, Historic Commercial Approval In Sight
Intellia Therapeutics remains a Buy, driven by two pivotal in vivo gene therapy catalysts: Lonvo-Z for HAE and Nex-Z for ATTR amyloidosis. Lonvo-Z's Phase 3 data met all endpoints with an 87% attack reduction, but market reaction was muted due to safety concerns and the competitive landscape. The FDA lifted clinical holds on Nex-Z Phase 3 trials, enabling advancement in a $16.8bn ATTR market with a differentiated one-time treatment profile.
Intellia Therapeutics, Inc. (NTLA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Intellia Therapeutics, Inc. (NTLA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
NTLA Q1 Earnings Beat Estimates, Revenues Miss Mark, Pipeline in Focus
Intellia cuts its Q1 loss, advances late-stage gene-editing programs and plans a 2027 launch for lonvo-z after strong phase III HAE data.
Intellia Therapeutics, Inc. (NTLA) Reports Q1 Loss, Misses Revenue Estimates
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to a loss of $1.1 per share a year ago.
Intellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Intellia Therapeutics (NTLA) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
